External beam radiotherapy is associated with a 10% survival advantage in women with deeply myoinvasive, high-grade endometrial cancer only, but women at lower risk of recurrence do not benefit.

Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women.

The OncoSignature multiplex immunofluorescence assay received breakthrough device designation from the FDA for identifying patients with endometrial cancer who may benefit from ACR-368 (prexasertib) ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

A CA 125 test measures the amount of protein in a person's blood, which helps test for cancer, the Mayo Clinic explains. An elevated reading doesn't automatically mean cancer however, as it can also ...

As a result, semaglutide and its fellow glucagon-like peptide-1 drugs are spawning a tremendous ... These include hormonal cancers like uterine cancer, as well as epithelial cancers, such as ...